52 related articles for article (PubMed ID: 20920877)
1. Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial.
Yoshino T; Hasegawa Y; Takahashi S; Monden N; Homma A; Okami K; Onozawa Y; Fujii M; Taguchi T; de Blas B; Beier F; Tahara M
Jpn J Clin Oncol; 2013 May; 43(5):524-31. PubMed ID: 23479384
[TBL] [Abstract][Full Text] [Related]
2. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Bossi P; Miceli R; Locati LD; Ferrari D; Vecchio S; Moretti G; Denaro N; Caponigro F; Airoldi M; Moro C; Vaccher E; Sponghini A; Caldara A; Rinaldi G; Ferrau F; Nolè F; Lo Vullo S; Tettamanzi F; Hollander L; Licitra L
Ann Oncol; 2017 Nov; 28(11):2820-2826. PubMed ID: 28950305
[TBL] [Abstract][Full Text] [Related]
3. Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer.
Fuchs H; Pammer J; Minichsdorfer C; Posch D; Kornek G; Aretin MB; Fuereder T
Med Oncol; 2018 Feb; 35(3):32. PubMed ID: 29411154
[TBL] [Abstract][Full Text] [Related]
4. An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.
Péron J; Polivka V; Chabaud S; Poupart M; Ceruse P; Ramade A; Girodet D; Zrounba P; Fayette J
BMC Cancer; 2014 Jul; 14():504. PubMed ID: 25011678
[TBL] [Abstract][Full Text] [Related]
5. VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis.
Nicholson S; Tovey H; Elliott T; Burnett SM; Cruickshank C; Bahl A; Kirkbride P; Mitra AV; Thomson AH; Vasudev N; Venugopal B; Slade R; Tregellas L; Morgan B; Hassall A; Hall E; Pickering LM
Br J Cancer; 2022 Jan; 126(1):34-41. PubMed ID: 34671131
[TBL] [Abstract][Full Text] [Related]
6. Association of Low and Intermediate Combined Positive Scores With Outcomes of Treatment With Pembrolizumab in Patients With Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: Secondary Analysis of Keynote 048.
Yu Y; Zakeri K; Sherman EJ; Lee NY
JAMA Oncol; 2022 Aug; 8(8):1216-1218. PubMed ID: 35679031
[TBL] [Abstract][Full Text] [Related]
7. Oral metronomic therapy as a resource-adaptive palliative strategy for recurrent/metastatic head and neck squamous cell cancers.
Kaul P; Garg PK
Oral Oncol; 2023 Nov; 146():106576. PubMed ID: 37742471
[No Abstract] [Full Text] [Related]
8. Personalized Treatment of Recurrent, Metastatic Head and Neck Cancer Guided by Patient-Derived Xenograft Models.
Black MD; Yoo J; Fung K; MacNeil D; Palma DA; Mymryk JS; Kuruvilla S; Barrett JW; Winquist E; Nichols AC
Cureus; 2024 Feb; 16(2):e53645. PubMed ID: 38449937
[TBL] [Abstract][Full Text] [Related]
9. Correction: Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study.
WakasakiI T; Manako T; YasumatsuI R; Hara H; Toh S; Masuda M; YamauchiID M; Kuratomi Y; Nishimura E; Takeuchi T; Matsuo M; Jiromaru R; Hashimoto K; Komune N; Nakagawa T
PLoS One; 2024; 19(5):e0303720. PubMed ID: 38722895
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of
Al-Khafaji ASK; Pantazi P; Acha-Sagredo A; Schache A; Risk JM; Shaw RJ; Liloglou T
Oncol Lett; 2020 Mar; 19(3):2502-2507. PubMed ID: 32194751
[No Abstract] [Full Text] [Related]
11. Cytotoxic effect of Erythroxylum daphnites extract is associated with G1 cell cycle arrest and apoptosis in oral squamous cell carcinoma.
Elias ST; Macedo CC; Simeoni LA; Silveira D; Magalhães PO; Lofrano-Porto A; Coletta RD; Neves FA; Guerra EN
Cell Cycle; 2016; 15(7):948-56. PubMed ID: 26918580
[TBL] [Abstract][Full Text] [Related]
12. Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol.
Ritter M; Teudt IU; Meyer JE; Schröder U; Kovács G; Wollenberg B
Radiat Oncol; 2016 Jan; 11():6. PubMed ID: 26792072
[TBL] [Abstract][Full Text] [Related]
13. Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer.
Fujii M
Int J Clin Oncol; 2014 Apr; 19(2):220-9. PubMed ID: 24578179
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
de Mello RA; Gerós S; Alves MP; Moreira F; Avezedo I; Dinis J
PLoS One; 2014; 9(2):e86697. PubMed ID: 24516537
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab: its unique place in head and neck cancer treatment.
Specenier P; Vermorken JB
Biologics; 2013; 7():77-90. PubMed ID: 23723688
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens.
Massa E; Dessì M; Gaspardini G; Saba F; Cherchi V; Mantovani G
Oral Oncol; 2010 Nov; 46(11):818-21. PubMed ID: 20920877
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
[TBL] [Abstract][Full Text] [Related]
18. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
[TBL] [Abstract][Full Text] [Related]
19. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Herbst RS; Arquette M; Shin DM; Dicke K; Vokes EE; Azarnia N; Hong WK; Kies MS
J Clin Oncol; 2005 Aug; 23(24):5578-87. PubMed ID: 16009949
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
